Company Capstone Therapeutics Corp Other OTC
Equities
US14068E1091
Biotechnology & Medical Research
Business Summary
Sales per Business
USD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Novel Peptides and Other Molecules
100.0
%
| 67 | 100.0 % | 62 | 100.0 % | -7.84% |
Sales per region
USD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 67 | 100.0 % | 62 | 100.0 % | -7.84% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Michael Toporek
CEO | Chief Executive Officer | 59 | 17-07-13 |
Edward Schultz
DFI | Director of Finance/CFO | - | - |
Matthew Lipman
BRD | Director/Board Member | 45 | 17-07-13 |
Jock Holliman
BRD | Director/Board Member | 70 | 87-08-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Jock Holliman
BRD | Director/Board Member | 70 | 87-08-31 |
Michael Toporek
CEO | Chief Executive Officer | 59 | 17-07-13 |
Matthew Lipman
BRD | Director/Board Member | 45 | 17-07-13 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 157,610 | 157,610 ( 100.00 %) | 0 | 100.00 % |
Company contact information
Capstone Therapeutics Corp.
1275 West Washington Street Suite 104
85281, Tempe
+602-286-5520
http://www.capstonethx.comSector
1st Jan change | Capi. | |
---|---|---|
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |